AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Financial_NN
Statements_NOMZ
Form_NN
20-F_NN
Information_NOMZ
2004_CD
89_CD
11_CD
Fixed_VBN
asset_NN
investments_NOMZ
continued_VBD
Share_NN
of_PIN
joint_JJ
venture_NN
assets_NN
and_PHC
liabilities_NOMZ
2004_CD
2003_CD
$_$
m_CD
$_$
m_CD
Gross_NN
assets_NN
174_CD
Gross_NN
liabilities_NOMZ
174_CD
The_DT
group_NN
disposed_VBD
of_PIN
its_PIT
joint_JJ
venture_NN
Advanta_NN
BV_NN
on_PIN
1_CD
September_NN
2004_CD
._.
The_DT
profit_NN
on_PIN
disposal_NN
is_VPRT [PASS]
disclosed_VBN [PUBV]
in_PIN
Note_NN
3_CD
._.
12_CD
Stocks_NN
2004_CD
2003_CD
$_$
m_CD
$_$
m_CD
Raw_NN
materials_NN
and_PHC
consumables_NN
646_CD
715_CD
Stocks_NN
in_PIN
process_NN
970_CD
1,206_CD
Finished_VBN
goods_NN
and_PHC
goods_NN
for_PIN
resale_NN
1,404_CD
1,101_CD
3,020_CD
3,022_CD
13_CD
Debtors_NN
2004_CD
2003_CD
$_$
m_CD
$_$
m_CD
Amounts_NN
due_JJ
within_PIN
one_CD
year_NN
Trade_NN
debtors_NN
3,636_CD
3,260_CD
Less_RB
:_:
Amounts_NN
provided_VBN [WZPAST]
for_PIN
doubtful_JJ
debts_NN
46_CD
57_CD
3,590_CD
3,203_CD
Deferred_VBN
taxation_NOMZ
Note_NN
5_CD
623_CD
732_CD
Other_JJ
debtors_NN
492_CD
508_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
1,110_CD
1,093_CD
5,815_CD
5,536_CD
Amounts_NN
due_JJ
after_IN
more_EMPH
than_PIN
one_CD
year_NN
Deferred_VBN
taxation_NOMZ
Note_NN
5_CD
159_CD
165_CD
Other_JJ
debtors_NN
78_CD
32_CD
Prepayments_NOMZ
and_CC
accrued_VBN
income_NN
222 227 459 424_CD
6,274_CD
5,960_CD
Figures_NN
include_VPRT
prepaid_VBN
pension_NN
costs_NN
Note_VPRT [PRIV]
28_CD
._.
Provisions_NN
for_PIN
doubtful_JJ
debts_NN
2004 2003 2002_CD
$_$
m_CD
$_$
m_CD
$_$
m_CD
Balance_NN
at_PIN
beginning_GER
of_PIN
year_NN
57_CD
56_CD
42_CD
Profit_NN
and_PHC
loss_NN
account_NN
charge_NN
811_CD
Amounts_NN
utilised_JJ
and_PHC
other_JJ
movements_NOMZ
11_CD
7_CD
3_CD
Balance_NN
at_PIN
end_NN
of_PIN
year_NN
46_CD
57_CD
56_CD
